Cutanos

Cutanos specializes in dermal targeted delivery systems aimed at delivering antigens to specialized immune cells known as dendritic cells (DCs). This technology is designed to enable innovative vaccines and immunotherapies, particularly for cancer and autoimmune diseases. The company's core product, the Langerhans Cell Targeted Delivery System (LC TDS), ensures precise targeting of antigens to specific subsets of DCs, minimizing off-target effects and unwanted side effects. The LC TDS can be applied using minimally invasive techniques, making it a painless and convenient option for patients. Cutanos operates in the biotechnology and healthcare market, primarily serving pharmaceutical companies and research institutions focused on immunotherapy and vaccine development. The business model revolves around licensing its proprietary technology and forming strategic partnerships for co-development and commercialization. Revenue is generated through licensing fees, milestone payments, and royalties on product sales.

Keywords: dermal delivery, dendritic cells, immunotherapy, cancer vaccines, autoimmune diseases, Langerhans cells, precision medicine, nanoparticle targeting, biotechnology, healthcare.